{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:52:27Z","timestamp":1792173147778,"version":"4.4.0"},"reference-count":15,"publisher":"Cambridge University Press (CUP)","issue":"7","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0899823X20012994_as1\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) nasal swabs are utilized to guide the discontinuation of empiric MRSA therapy. In multiple studies, MRSA nasal swabs have been shown to have a negative predictive value (NPV) of ~99% in non-oncology patients with pneumonia and other infections. We evaluated the performance characteristics of a negative MRSA nasal swab in the acute myeloid leukemia (AML) populaion to determine its NPV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20012994_as2\">\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20012994_as3\">\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>This study included adult AML patients with a suspected infection and a MRSA nasal swab collected between 2013 and 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20012994_as4\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MRSA nasal swab and culture-documented infections were identified to determine the sensitivity, specificity, NPV, and positive predictive value of the MRSA nasal swabs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20012994_as5\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 194 patients were identified, and 484 discrete encounters were analyzed. Overall, 468 (97%) encounters had a negative MRSA nasal swab upon admission with no cultured documented MRSA infection during their hospitalization. However, 3 encounters (0.6%) had a negative MRSA nasal swab with a subsequent cultured documented MRSA infection during their admission. Identified infections were bacteremia (n = 2) and confirmed pneumonia (n = 1). MRSA nasal swab had a sensitivity of 62% (95% CI, 0.24\u20130.91), specificity of 98% (95% CI, 0.96\u20130.99), positive predictive value of 38% (95% CI, 0.21\u20130.6), and NPV of 99% (95% CI, 0.98\u20131).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20012994_as6\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A negative MRSA nasal swab has a 99% NPV for subsequent MRSA infections in AML patients with no prior history of MRSA colonization or infection. Based on these findings, a negative MRSA nasal swab can help guide de-escalation of empiric MRSA antibiotic therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/ice.2020.1299","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T03:25:57Z","timestamp":1606188357000},"page":"853-856","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of the negative predictive value of methicillin-resistant\n                    <i>Staphylococcus aureus<\/i>\n                    nasal swab screening in patients with acute myeloid leukemia"],"prefix":"10.1017","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-7579","authenticated-orcid":false,"given":"Sarah K.","family":"Perreault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailee","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna S.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Topal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"S0899823X20012994_ref5","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140820"},{"key":"S0899823X20012994_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13059"},{"key":"S0899823X20012994_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq147"},{"key":"S0899823X20012994_ref12","doi-asserted-by":"publisher","DOI":"10.1086\/376637"},{"key":"S0899823X20012994_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0778-5"},{"key":"S0899823X20012994_ref9","unstructured":"9. National Healthcare Safety Network (NHSN). Patient safety component manual, 2019. Centers for Disease Control and Prevention website. https:\/\/www.cdc.gov\/nhsn\/acute-care-hospital\/index.html. Published 2019. Accessed October 29, 2020."},{"key":"S0899823X20012994_ref4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01805-13"},{"key":"S0899823X20012994_ref14","doi-asserted-by":"publisher","DOI":"10.1086\/597291"},{"key":"S0899823X20012994_ref15","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02972-13"},{"key":"S0899823X20012994_ref10","first-page":"197","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients\u2014United States, 2005","volume":"56","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"key":"S0899823X20012994_ref1","unstructured":"1. Prevention and treatment of cancer-related infections (version 1.2019). National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Published 2019. Accessed October 29, 2020."},{"key":"S0899823X20012994_ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318243168e"},{"key":"S0899823X20012994_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2019.09.005"},{"key":"S0899823X20012994_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"S0899823X20012994_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.308"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X20012994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T11:44:47Z","timestamp":1634298287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X20012994\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0899823X20012994"],"URL":"https:\/\/doi.org\/10.1017\/ice.2020.1299","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"\u00a9 The Author(s), 2020. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}